CRP and cancer: Additionally, the platelet–albumin ratio and cancer inflammation prognostic index have been validated in multiple cohorts as predictors of infectious complications and mortality.[32] Notably, bibliometric analyses of immune-related complications in cancer immunotherapy highlight that systemic inflammatory responses (e.g., elevated CRP, reduced complement levels) are independent risk factors for poor prognosis[33]: a finding consistent with our patient’s clinical course (persistent inflammation, hypocomplementemia).